Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | CA7 | P43166 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.32 |
| ▸ | MBNL1 | Q9NR56 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1060727 | 0.92 | CA1 (0.38) | CA1CA2CA7ALDH1A1MAPT | |
| SCHEMBL4467853 | 0.90 | CA1 (0.37) | CA1CA2CA7ALDH1A1MAPT | |
| SCHEMBL4473277 | 0.87 | MAPT (0.42) | CA1CA2CA7ALDH1A1MAPT | |
| SCHEMBL1062033 | 0.85 | CA1 (0.38) | CA1CA2CA7ALDH1A1MAPT | |
| SCHEMBL4467254 | 0.84 | CA1 (0.38) | CA1CA2CA7ALDH1A1MAPT | |
| SCHEMBL1064841 | 0.82 | HSP90AB1 (0.44) | CA1CA2CA7ALDH1A1MAPT | |
| SCHEMBL1065254 | 0.81 | CA1 (0.40) | CA1CA2CA7MAPTRXFP1 | |
| SCHEMBL1064665 | 0.81 | ALDH1A1 (0.34) | CA1CA2CA7ALDH1A1LMNA | |
| SCHEMBL1065783 | 0.80 | PPARG (0.42) | CA1CA2CA7ALDH1A1MAPT | |
| SCHEMBL4475432 | 0.79 | MAPT (0.35) | CA1CA2CA7ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | claimed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | claimed |
| US-20060293348-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-28 | — | — | US | claimed |
| EP-1499320-A4 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2006-05-17 | — | — | EP | claimed |
| CN-1646131-A | Novel compounds | SMITHKLINE BEECHAM CORP (US) | 2005-07-27 | — | — | CN | claimed |
| EP-1499320-A1 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2005-01-26 | — | — | EP | claimed |
| WO-2003088972-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-30 | — | — | WO | claimed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629350-B2 | Compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| EP-1499320-B1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060293348-A1 | Novel compounds | SMITHKLINE BEECHAM CORPORATION (US) | 2006-12-28 | — | — | US | disclosed |
| CN-1646131-A | Novel compounds | SMITHKLINE BEECHAM CORP (US) | 2005-07-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293348-A1 | Novel compounds | MAPKAPK2, CREBBP, CDC42BPB | CA1 4694/4885CA2 3847/4885CA7 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.